An additional case of indolent CD4+ cytotoxic CAR+ T-cell lymphoma in the small intestine was reported in a patient who received cilta-cel therapy; numerous genetic alterations were identified ...

Indolent CD4+ cytotoxic chimeric antigen receptor (CAR) T-cell lymphoma involving the small intestine was diagnosed in a patient who had previously received ciltacabtagene autoleucel (cilta-cel ...

Stage 4 lymphoma is a blood cancer that has spread outside of the lymph nodes to other parts of the body. Learn the symptoms, ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response ...

The specific treatment course and prognosis for T-cell lymphoma depends on the subtype — of which there are many — and how advanced the cancer is. Hodgkin lymphoma involves a type of cancer ...

Peripheral T cell lymphoma, not otherwise specified (PTCL NOS ... Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate throughout the body in your bloodstream.

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

Adult T-cell leukemia–lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes ...

is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess MB-105's safety and efficacy in approximately 46 ...

"And, importantly, while lymphoma-bearing animals that received ... stages of the disease whose treatment requires a lot of cytotoxic T cell potential. In translating TES further toward human ...